“…Recently, our research group evaluated the efficacies of the Idelalisib, SRPIN340, and Idelalisib/SRPIN340 combination in 3D spheroids derived from PCa and other solid tumor cell lines (22Rv1, PC-3, LNCaP, MDA PCa 2b, DU-145, C4-2B, HT-29, SW620, A549, H1299, MSA MB 231, and MCF-7). Our results suggested that combined Idelalisib/SRPIN340 therapy resulted in a synergistic effect on inhibiting PCa and other solid tumor spheroids expressing PI3Kδ isoforms [142]. Additionally, we established PCa organoids from LNCaP, C4-2B, 22Rv1 and MDA PCa 2b cells for exploring the mTOR/AR signaling in the in African American (AA) PCa disparities and CRPC progression.…”